Infection After Open Long Bone Fractures: Can We Improve on Prophylaxis?


Journal

The Journal of surgical research
ISSN: 1095-8673
Titre abrégé: J Surg Res
Pays: United States
ID NLM: 0376340

Informations de publication

Date de publication:
12 2021
Historique:
received: 17 03 2020
revised: 14 03 2021
accepted: 26 05 2021
pubmed: 20 7 2021
medline: 7 4 2022
entrez: 19 7 2021
Statut: ppublish

Résumé

Current standards recommend antibiotic prophylaxis administered after open fracture injury. The purpose of this study was to assess culture results in patients with open fracture-associated infections, hypothesizing that cultures obtained do not vary by Gustilo-Anderson (GA) classification. We examined cultured bacterial species from patients with open long bone fractures that underwent irrigation and debridement at a Level 1 trauma center (2008-2016), evaluating our current and two hypothetical antibiotic protocols to assess whether they provided appropriate coverage. The antibiotic protocols included protocols 1 (cefazolin, with gentamicin added for type III fractures), 2 (vancomycin and cefepime) and 3 (ceftriaxone). GA classification was not associated with bacterial gram stain (P = 0.161), nor was it predictive of mono- versus polymicrobial infection (P = 0.094). Of 42 culture-positive infections, 31 were type III and 11 were type I or II fractures. 27% of the infections for type I or II fractures were caused by organisms targeted by protocol 1 (OR 0.18, 95% CI 0.04-0.82; P = 0.027). There was no difference in coverage by fracture type among protocol 2 (P = 0.771) or protocol 3 (P = 0.891). For type III fractures, protocol 2 provided 94% appropriate coverage compared to 68% and 61% coverage by protocols 1 and 3, respectively. For open fractures complicated by infection, isolated bacterial organisms do not correlate with GA open fracture classification, suggesting that hypothetical protocol 2 should be used for all fracture types. Protocol 2's broad coverage, across all GA fracture types, may prevent infection by organisms not covered by current antibiotic prophylaxis.

Identifiants

pubmed: 34280663
pii: S0022-4804(21)00362-0
doi: 10.1016/j.jss.2021.05.048
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Ceftriaxone 75J73V1629
Cefazolin IHS69L0Y4T

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

33-39

Informations de copyright

Copyright © 2021. Published by Elsevier Inc.

Auteurs

Amanda Mener (A)

Emory University School of Medicine, Atlanta, GA.

Christopher Staley (C)

Philadelphia College of Osteopathic Medicine, Suwanee, GA.

Adam Boissonneault (A)

Department of Orthopaedic Surgery, Emory University School of Medicine, Atlanta, GA.

William Reisman (W)

Department of Orthopaedic Surgery, Emory University School of Medicine, Atlanta, GA.

Mara Schenker (M)

Department of Orthopaedic Surgery, Emory University School of Medicine, Atlanta, GA.

Roberto Hernandez-Irizarry (R)

Department of Orthopaedic Surgery, Emory University School of Medicine, Atlanta, GA. Electronic address: rchern2@emory.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH